[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-function":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,48,76,106,158,182,206,237],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100565720","targeting-aging-with-a-ketone-ester-for-function-in-frailty-100565720",false,"NCT06645847","Targeting Aging With a Ketone Ester for Function in Frailty","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Evaluate the Effect of a Ketone Ester on Muscle and Immune Function in Older Men and Women Who Are at Risk for Strength and Mobility Decline","TAKEOFF","Inclusion Criteria:\n\n1. Subject is greater than or equal to 65 years of age, inclusive at Screening.\n2. Passes the gait speed criteria at Screening.\n3. Minimum body weight of 50 kgs at Screening.\n4. Subject is willing and able to comply with all study procedures including randomization into any of the experimental groups, maintenance of habitual dietary intake, exercise and medication and supplement use, blood draws and the following prior to test visits: fasting (≥10 h; water only), no alcohol (≥ 10 h), no cannabis products (≥10 h) and no exercise (≥ 10 h).\n5. Subject understands the study procedures and can provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Subject is non ambulatory.\n2. Subject has a CSHA clinical frailty score \\> 5.\n3. Subject requires assistance with any activity of daily living, excluding continence.\n4. Subject lives in an institutional setting (skilled nursing facility or residential care facility for the elderly).\n5. Subject is a female who has not passed menopause.\n6. Subject is unable to converse in English (or Spanish, if available at the study site).\n7. Subject has been hospitalized within 30 days of Screening.\n8. Subject has any physical limitation that would prevent them from performing 1RM leg press based on Medical Officer judgement.\n9. Subject has an abnormal laboratory test result(s) of clinical importance at Screening, indicating unstable chronic disease of major organ dysfunction that requires urgent evaluation, at the discretion of the Medical Officer. One re-test will be allowed on a separate day prior to Visit 1, for subjects with abnormal laboratory test results. Additional clinical information may be gathered from the participant if needed to interpret the urgency of laboratory abnormalities (e.g. recent laboratory trends if an electrolyte is abnormal).\n10. Subject has uncontrolled hypercholesterolemia on screening labs.\n11. Subject has a history or presence of acute or uncontrolled and\u002For clinically active pulmonary (chronic obstructive pulmonary disease \\>= Gold 3), cardiac (e.g. \\>= New York Heart Association class III), hepatic (cirrhosis), renal (chronic kidney disease stage \\>= IIIb), endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and\u002For anxiety disorders) or biliary disorders. \"Uncontrolled\" and \"clinically active\" are per the judgement of the Medical Officer. Stable chronic disease is not an exclusion criterion unless specified. Chronic disease that is managed with the patient's physician per shared decision-making, even if sub optimally by typically recommended care, is not an exclusion criterion unless uncontrolled or clinically active.\n12. Subject has a clinically important gastrointestinal condition that would potentially interfere with the evaluation of the study beverage \\[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the Medical Officer), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the Investigator, history of gastrointestinal ulcers or bleeding, history of pancreatitis, history of hiatal hernia, history of Barrett's esophagus, or history of esophageal cancer\\].\n13. Heavy drinking (For women, 8 or more drinks per week. For men, 15 or more drinks per week).\n14. Subject has a history of alcohol or substance abuse.\n15. Subject has been instructed not to consume alcohol for medical reasons.\n16. Subject has a known, clinically important allergy, intolerance, or sensitivity to any of the ingredients in the study beverages, including soy and milk protein.\n17. Subject has uncontrolled hypertension as defined by the blood pressure measured at Screening. For subjects with elevated blood pressure at Screening, they are allowed for the purpose of this criteria to submit home readings from three separate days, or to have a repeat reading taken at the study site on a separate day before Visit 1.\n18. Subject is undergoing treatment or active surveillance for cancer or has been diagnosed with cancer in the prior two years, except for non-melanoma skin cancer. Active surveillance is defined as regular imaging or laboratory tests at a frequency greater than annually. Cancer under long-term monitoring such as stable chronic lymphocytic leukemia need not be an exclusion, on the discretion of the Medical Officer.\n19. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n20. Chronic antibiotic use (e.g. expected to be ongoing, regardless of frequency, throughout the study period).\n21. Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein\u002Flow carbohydrate or has used weight-loss medications (including over-the-counter medications and\u002For supplements) or programs within 30 days of Screening.\n22. Subject has followed a ketogenic diet or used ketone supplements (ketone salts or esters, and medium chain triglycerides) within 30 days of Screening.\n23. Subject has a condition the Medical Officer believes would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.\n24. Subject works nights or shifts that means it is not possible to maintain a consistent meal schedule during the study.",true,"ALL","65 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to find out if a food supplement that contains a naturally occurring substance, ketones, can help to improve strength and general wellness in adults at, or over the age of 65 years who are experiencing a slight decline in their physical function.\n\nParticipation will involve a screening visit and 4 additional study visits over the course of 20 weeks. After being assessed for eligibility, study participants will be sorted into two groups at random and consume either a ketone or placebo supplement at home every day for 20 weeks. Both study products can cause gastro-intestinal side effects in some individuals. At all study visits, subjects will provide blood samples. At three study visits, subjects will be asked to complete physical performance tests, provide blood, stool and urine samples. They will also complete questionnaires during three study visits to assess physical function, markers of inflammation, and other aspects of general well-being.\n\nThe study enrolls at three sites across the United States, in California (Buck Institute), Ohio (Ohio State University), and Connecticut (University of Connecticut). The study is coordinated by the San Francisco Coordinating Center (California Pacific Medical Center).",[28,29,30,31],"Frail Elderly","Aging","Immune Function","Muscle Function",[33,34],"ketone ester","exogenous ketone","RECRUITING","2026-03-12",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":39},"2025-02-05",{"date":43,"type":22},"2028-04-01",{"name":45,"class":46},"Buck Institute for Research on Aging","OTHER",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100597062","clinical-study-on-laparoscopic-resection-of-splenic-artery-aneurysm-with-preservation-of-spleen-100597062","NCT07053605","Clinical Study on Laparoscopic Resection of Splenic Artery Aneurysm With Preservation of Spleen","Inclusion Criteria:\n\n* Asymptomatic splenic artery aneurysms with a diameter\\>2 cm,ruptured splenic artery aneurysms,and splenic artery aneurysms with a diameter increase\\>0.5 cm\u002Fyear.\n\nAneurysm located in the main trunk of the splenic artery. Informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with malignancies Hepatic cirrhosis with portal hypertension peptic ulcer disease Recent peptic ulcer disease History of Hemorrhagic stroke Pregnancy hematological diseases Uncontrolled Hypertension Human immunodeficiency virus (HIV) infection","18 Years",{"count":56,"type":22},10,[25],"In this study, researchers examined the changes in related indicators such as immune function, splenic vein,proper hepatic artery, and portal venous hemodynamics following laparoscopic resection of a splenic artery aneurysm. We determined the changes in these patient-related indicators after surgical treatment and whether these changes could improve patient outcomes.",[60,30,61],"Splenic Artery Aneurysm","Hemodynamics",[63,64,65,61],"Laparoscopy","resection of splenic artery aneurysm","Immune function","2025-07-01",{"date":68,"type":39},"2025-07-08",{"date":70,"type":39},"2025-06-23",{"date":72,"type":22},"2027-06-30",{"name":74,"class":46},"Northern Jiangsu People's Hospital",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100572742","the-impact-of-a-48-hour-fast-with-or-without-exercise-on-immune-cell-metabolism-and-glycemic-control-in-healthy-active-adults-100572742","NCT06737224","The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Control in Healthy Active Adults","The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Function, Bioenergetics, and Glycemic Control in Healthy Active Adults: a Randomized Crossover Trial","FASTEX","Inclusion Criteria:\n\n* Aged between 19 and 35 years.\n* Physically active (engaging in ≥150 minutes of weekly moderate to vigorous physical activity).\n\nExclusion Criteria:\n\n* History of cardiometabolic diseases or inflammatory diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease).\n* Individuals currently following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consuming ketogenic supplements (e.g., exogenous ketone drinks).\n* Cigarette\u002Fvaping smoking.\n* Physical limitation that will impair the ability of the participant to perform exercise.\n* Individuals having a body mass index (BMI) over 30 kg\u002Fm2.\n* Cancer diagnosis in the past 5 years.\n* Taking anti-inflammatory drugs (e.g., ibuprofen, aspirin, naproxen).\n* Being unable to read or communicate in English.","19 Years","35 Years",{"count":87,"type":22},15,[25],"Many individuals engage in fasting for its purported health benefits but the effects of fasting on immune cell and whole body metabolism are not well understood in humans. Moreover, how exercising during a prolonged fast impacts immunometabolic outcomes is unclear. This study will determine how a 2 day fast - performed with or without daily exercise - impacts immune cell bioenergetics, immune cell function, and whole-body glycemic control in healthy active individuals.",[91,30,92],"Fasting","Glucose Tolerance",[94,95,96],"Exercise","Immunometabolism","Glycemic control","2025-03-04",{"date":99,"type":39},"2025-03-07",{"date":101,"type":39},"2025-01-10",{"date":103,"type":22},"2025-08-01",{"name":105,"class":46},"University of British Columbia",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":128,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":75},"100577217","a-randomized-double-blind-study-to-assess-the-effect-of-a-postbiotic-on-oxidative-stress-and-exercise-performance-100577217","NCT06795425","A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance","A Randomized, Double-Blinded, Placebo-Controlled, Parallel Study, to Assess the Effect of a Novel Postbiotic Blend on Exercise Induced Oxidative Stress Markers and Exercise Performance","PBE","INCLUSION CRITERIA\n\nTo be eligible for inclusion, the participant must fulfill all of the following criteria:\n\n1. Male or female participants between 18 - 45 years of age\n2. Signed informed consent.\n3. Health, which is defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With research team and principal investigator discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase risk of study participation and the treatment or illness itself will not confound with desired study outcomes.\n4. Physically active, which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week at a rating of perceived intensity (RPE) of 4 or greater (out of 10)\n5. Body mass index values will range from \\>18.5 to \\\u003C 29.9 kg\u002Fm2 (Inclusive)41 (Weir and Jan 2024).\n6. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures.\n\nEXCLUSION CRITERIA\n\nParticipants will be excluded from the study if they meet any of the following criteria:\n\n1. Body mass index \\\u003C18.5 to \\\u003C29.9 kg\u002Fm2 (Inclusive)\n2. Use of antibiotics or probiotics in the previous 3 months\n3. Positive medical history and\u002For is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease or other diagnosed hepatic impairment.\n4. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n5. Diagnosed with major affective disorder or other significant psychiatric disorder or disturbance that required hospitalization or home intervention in the prior year.\n6. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n7. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, bile acid malabsorption, H.pylori infection, small intestine bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n8. Recently prescribed or change in dosage (within the past 6 months) of statin drug (i.e., Lipitor, Livalo, Crestor, Zocor, etc.), hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.), or psychiatric medications.\n9. Consumption (any dose or amount) of any nicotine-containing product (cigarette, cigar, vaping, etc.)\n10. Participants who are lactating, pregnant or planning to become pregnant.\n11. History of alcohol or substance abuse in the 12 months prior to screening\n12. Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol.\n13. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data.\n14. Extensive travel (\\>1 month) that will disrupt original outline of the study protocol.\n15. Participant is consuming a biotic product (pre-, pro-, syn-, or post-) or alters their diet resulting in a change in the amount of prebiotic, probiotic, or fermented foods that are consumed while in the study protocol.","45 Years",{"count":116,"type":22},80,[25],"This is a prospective, randomized, placebo controlled, double-blind study to assess the effects of a postbiotic blend on exercise induced oxidative stress markers and exercise performance in healthy adult.",[120,121,122,123,30,124,125,126,127],"Oxidative Stress","Healthy","Exercise-induced Muscle Damage","Exercise-induced Muscle Soreness","Gut Health","Microbiome Analysis","Exercise Performance","Exercise Metabolism",[129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147],"oxidative stress","antioxidants","postbiotics","ergogenic aid","exercise performance","muscle damage","recovery","gut microbiome","immune function","sleep quality","anxiety","recreationally active","inflammation","endurance training","fecal microbiota","nutritional supplement","aerobic exercise","biomarkers","clinical trial","NOT_YET_RECRUITING","2025-01-21",{"date":151,"type":39},"2025-01-28",{"date":153,"type":22},"2025-02-01",{"date":155,"type":22},"2026-01-01",{"name":157,"class":46},"Lindenwood University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":75},"100545237","investigating-the-role-of-energy-balance-modification-on-health-responses-in-chronic-lymphocytic-leukaemia-100545237","NCT06379282","Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia","HIT-CLL","Inclusion Criteria:\n\n* Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.\n* Male or female ≥ 18 years of age\n* Able to walk on a treadmill or cycle on an ergometer\n* Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)\n\nExclusion Criteria:\n\n* Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.\n* Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.\n* Absolute contraindications to exercise: Recent (\\\u003C6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.\n* Significant orthopaedic limitations, musculoskeletal disease and\u002For injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.\n* Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease\n* Uncontrolled blood pressure (≥180\u002F90) at rest\n* Known concurrent HIV, Hepatitis B or Hepatitis C\n* Unable to comply with other study requirements",{"count":166,"type":22},132,[25],"This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised\u002Fsemi-supervised exercise only, exercise + nutritional guidance, or no exercise.",[170,171,31,30,172],"Chronic Lymphocytic Leukemia","Frailty","Lipid Cell; Tumor","2024-04-23",{"date":175,"type":39},"2024-04-24",{"date":177,"type":39},"2022-10-14",{"date":179,"type":22},"2026-08-01",{"name":181,"class":46},"University of Surrey",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":189,"minAge":54,"maxAge":114,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":75},"100541138","pcos-immune-function-predicts-metformin-efficacy-100541138","NCT06325956","PCOS Immune Function Predicts Metformin Efficacy","Prediction of Immune Status on the Efficacy of Metformin in the Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* aged 18-45 years\n* Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003)\n\nExclusion Criteria:\n\n* Pregnant women;\n* Hyperthyroidism or hypothyroidism\n* Severe liver and kidney function injury\n* Cancer patients;\n* Associated with severe infection, severe anemia, neutropenia and other blood system diseases;\n* Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;\n* Patients with mental illness or intellectual disability;\n* Have taken drugs for PCOS treatment in the last three months;\n* Have a long history of taking hormone therapy;\n* Currently or recently participating in another clinical trial.","FEMALE",{"count":191,"type":22},100,[25],"In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.",[195,196,30],"Polycystic Ovary Syndrome","Metformin","2024-03-21",{"date":199,"type":39},"2024-03-22",{"date":201,"type":39},"2024-03-16",{"date":203,"type":22},"2026-07-01",{"name":205,"class":46},"Shanghai 10th People's Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":17,"sex":189,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":75},"100483093","12--bangladesh-center-for-global-environmental-and-occupational-health--bangladesh-100483093","NCT05570552","1\u002F2- Bangladesh Center for Global Environmental and Occupational Health- Bangladesh","Long Term Effects of Household Air Pollution (HAP) Reduction on Cardio-pulmonary and Immune Function Outcomes - a Household Level Randomized mHealth Intervention Trial","GEOHealth-II","Inclusion Criteria:\n\n* Participants in the previous GEOHEALTH round-I study\n* Aged between 25 and 70 years\n* Live in biomass-using home with traditional stoves\n* Non-smoker and live with non-smokers\n* Exposed to \\\u003C10 µg\u002FL of water arsenic\n\nExclusion Criteria:\n\n* Known to have immune related illness or taking any prescription medication (particularly those that suppress or enhance immune function)\n* Known to have any clinical events of CVD or lung disease, including stroke or coronary heart disease.","25 Years","70 Years",{"count":217,"type":22},1000,[25],"Almost 3 billion people worldwide, including 89% people in Bangladesh, are exposed to harmful household air pollutants (HAP) emitted from combustion of biomass (wood, agricultural residue, cow dung, etc.) fuel use for cooking. While health risks associated with air-pollution have been reasonably well-studied in developed countries, there is little evidence on health benefits achievable by HAP reduction through clean fuel use, especially in low- and middle-income countries (LMICs). Earlier the investigators showed that Liquid Petroleum Gas (LPG) for 24 months, reduced personal PM2.5 exposure by 58.17 percent which induced novel changes in immune and inflammatory responses in the participants; however cardiopulmonary markers remained relatively stable in post-intervention assessment.\n\nIn this study, the investigators aim to evaluate the effects of mobile phone based (mHealth) Behavioural Change Communication (BCC) intervention on adoption and exclusive use of LPG. The investigators also aimed to observe whether long-term effects of HAP reduction can impact the subclinical measures of cardio-vascular and pulmonary dysfunction and regulate innate and inflammatory immune function among women and children in semi-rural settings in Bangladesh. The investigators will also investigate the influence of exposure to HAP on antibody response to vaccines (adaptive immunity). The BCC intervention will be provided by conducting a large household level randomized controlled trial by educational intervention using mHealth based technology. In addition, the investigators will continue following the cohort and will conduct rigorous and repeated personalized (24 hours) and area (over 5 days) assessments of PM2.5 and black carbon (BC) exposure to examine the long-term effects of HAP reduction on subclinical measures of cardio-pulmonary and immune dysfunction including effect of HAP exposure on antibody response to vaccine.",[221,222,223,30],"Air Pollution","mHealth Intervention","Cardiopulmonary Function",[225,226,227,65,228],"Mobile based Behavioral Change Communication intervention","Household air pollution reduction","Cardiopulmonary function","Clean fuel LPG","2024-03-20",{"date":199,"type":39},{"date":232,"type":39},"2023-06-20",{"date":234,"type":22},"2027-06",{"name":236,"class":46},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":247,"phases":4,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":75},"100531703","microecology-and-immunity-in-patients-with-anti-mda5-antibody-positive-dermatomyositis-and-interstitial-lung-disease-100531703","NCT06203249","Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease","Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.\n* Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.\n* Must have undergone bronchoalveolar lavage.\n* Age≥18 years old.\n* Patients who signed informed consent forms\n\nExclusion Criteria:\n\n* Patients who had other connective tissue diseases.\n* Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.\n* Pregnant or lactating patients.\n* The patient also participated in any other clinical trial.\n* Disagreement for inclusion in this study","100 Years",{"count":246,"type":22},50,"OBSERVATIONAL","The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.",[250,30,251],"Microbiome","Anti-MDA5 Antibody Positive Dermatomyositis","2024-01-10",{"date":254,"type":39},"2024-01-12",{"date":256,"type":22},"2024-01-20",{"date":258,"type":22},"2026-11-25",{"name":260,"class":46},"Chinese PLA General Hospital"]